Big Pharma · Oncology · United States

Novartis — Oncology in United States

Rare DiseaseOncologyImmunologyCardiometabolicNeurology
Commission a Novartis report

Novartis in United States — Oncology: Kisqali, and the 1 AXLRx report covering them with market-access, payer and competitive detail, every figure verified to a live source.

All areas Rare DiseaseOncology
Market: All United States
Market access — United States

Fabhalta covered via specialty pharmacy; complement franchise leverages the Soliris/Ultomiris access precedent.

AXLRx reports featuring Novartis — Oncology in United States
Breast Cancer HR+/HER2-
CI
CI Oncology CI TeamLaunch Lead

US Breast Cancer HR+/HER2- Competitive Intelligence

Only ribociclib has posted consistent overall-survival wins in the three-way first-line CDK4/6 contest. MONALEESA-2 showed 63.9 versus 51.4 months (HR 0.76). The real competition has moved downstream, where 2023 approvals of an oral SERD and an AKT inhibitor carve the post-CDK4/6 line by biomarker.

US In-Market Read report →